Your browser doesn't support javascript.
loading
The Genomic Landscape of Colorectal Cancer in the Saudi Arabian Population Using a Comprehensive Genomic Panel.
Alsolme, Ebtehal; Alqahtani, Saleh; Fageeh, Musa; Barakeh, Duna; Sharma, Nitesh K; Mangul, Serghei; Robinson, Heather A; Fathaddin, Amany; Hauser, Charlotte A E; Abedalthagafi, Malak.
Afiliación
  • Alsolme E; Genomic Research Department, King Fahad Medical City, Riyadh 12231, Saudi Arabia.
  • Alqahtani S; Royal Clinic and Hepatology Department, King Faisal Specialist Hospital and Research Center, Riyadh 11564, Saudi Arabia.
  • Fageeh M; Pathology Department, King Saud Medical City, Riyadh 12746, Saudi Arabia.
  • Barakeh D; Genomic Research Department, King Fahad Medical City, Riyadh 12231, Saudi Arabia.
  • Sharma NK; The Titus Family Department of Clinical Pharmacy, School of Pharmacy, University of Southern California, Los Angeles, CA 90007, USA.
  • Mangul S; The Titus Family Department of Clinical Pharmacy, School of Pharmacy, University of Southern California, Los Angeles, CA 90007, USA.
  • Robinson HA; Health eResearch, University of Manchester, Manchester M13 9PL, UK.
  • Fathaddin A; Department of Pathology, Collage of Medicine, King Saud University, Riyadh 11362, Saudi Arabia.
  • Hauser CAE; Laboratory for Nanomedicine, Biological & Environmental Science & Engineering (BESE) Division, King Abdullah University of Science and Technology (KAUST), Thuwal 23955, Saudi Arabia.
  • Abedalthagafi M; Computational Bioscience Research Center (CBRC), King Abdullah University of Science and Technology (KAUST), Thuwal 23955, Saudi Arabia.
Diagnostics (Basel) ; 13(18)2023 Sep 19.
Article en En | MEDLINE | ID: mdl-37761360
ABSTRACT

PURPOSE:

Next-generation sequencing (NGS) technology detects specific mutations that can provide treatment opportunities for colorectal cancer (CRC) patients. PATIENTS AND

METHODS:

We analyzed the mutation frequencies of common actionable genes and their association with clinicopathological characteristics and oncologic outcomes using targeted NGS in 107 Saudi Arabian patients without a family history of CRC.

RESULTS:

Approximately 98% of patients had genetic alterations. Frequent mutations were observed in BRCA2 (79%), CHEK1 (78%), ATM (76%), PMS2 (76%), ATR (74%), and MYCL (73%). The APC gene was not included in the panel. Statistical analysis using the Cox proportional hazards model revealed an unusual positive association between poorly differentiated tumors and survival rates (p = 0.025). Although no significant univariate associations between specific mutations or overall mutation rate and overall survival were found, our preliminary analysis of the molecular markers for CRC in a predominantly Arab population can provide insights into the molecular pathways that play a significant role in the underlying disease progression.

CONCLUSIONS:

These results may help optimize personalized therapy when drugs specific to a patient's mutation profile have already been developed.
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Diagnostics (Basel) Año: 2023 Tipo del documento: Article País de afiliación: Arabia Saudita

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Diagnostics (Basel) Año: 2023 Tipo del documento: Article País de afiliación: Arabia Saudita